Track Jasper Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Jasper Therapeutics Inc. Common Stock JSPR · Stock Open Jasper Therapeutics Inc. Common Stock in new tab

13.68 USD
EPS
-31.20
P/B
295.20
ROE
-255.05
Beta
3.04
Loading chart...
Key Metrics
Earnings dateMarch 9, 2027
EPS-31.20
Book Value0.05
Price to Book295.20
Debt/Equity19.11
% Insiders2.550%
Estimates
Forward P/E-0.70
Forward EPS-21.15

DCF valuation

Model fair value for Jasper Therapeutics Inc. Common Stock (JSPR)
Result
Sign in to run the valuation for JSPR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Jasper Therapeutics Inc. Common Stock Logo Jasper Therapeutics Inc. Common Stock Analysis (JSPR)

United States Health Care Official Website Stock

Is Jasper Therapeutics Inc. Common Stock a good investment? Jasper Therapeutics Inc. Common Stock (JSPR) is currently trading at 13.68 USD.

Earnings Schedule: Jasper Therapeutics Inc. Common Stock is expected to release its next earnings report on March 9, 2027. The market consensus estimate for Forward EPS is -21.15.

Investor FAQ

Does Jasper Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Jasper Therapeutics Inc. Common Stock?

Jasper Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 9, 2027. The company currently has a trailing EPS of -31.20.

Company Profile

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is headquartered in Redwood City, California.

Exchange Ticker
NMS (United States) JSPR
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Jan. 4, 2024 1:10
Nov. 6, 2026 1:30
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion